

THE EFFECTS OF COCAINE USE ON THE COURSE AND OUTCOME OF PREGNANCY

Novica Bojanić¹, Jelena Milenković¹, Darija Obradović², Jelena Bojanić³, Nataša Djindjić⁴, Stefan Ilić⁵

The epidemic of drug addiction is a significant public health issue worldwide. Through easy availability of cocaine, its use by childbearing women may have deleterious effects on the course and outcome of pregnancy.

Cocaine use during pregnancy causes: intrauterine growth retardation, abruptio of placenta, increased frequency of premature birth, premature rupture of the membranes, precipitous labor, meconium-stained amniotic fluid, stillbirth, neonatal necrotizing enterocolitis, neonatal bowel perforation, complete bilateral absence of the diaphragm, neonatal respiratory disorders, neonatal subcutaneous fat necrosis, sudden infant death syndrome, intimal fibromuscular dysplasia of numerous blood vessels, hearing impairment, retinal hemorrhages, fetal or maternal intracranial accident, rupture of the uterus, ruptured tubal ectopic pregnancy, placenta previa, changes in neonatal behavior, neonatal cardiac arrhythmias, various congenital anomalies, maternal myocardial infarction and long QT interval in a parturient.

Retrospective studies have shown that intrauterine exposure to cocaine causes major malformations in newborns: congenital heart defects, genitourinary, brain and skull anomalies, absence of limbs, ankyloglossia, hypothalamic hamartoblastoma, and Poland-Möbius syndrome.

Some authors suggest that there is a specific fetal cocaine syndrome and a link between the high incidence of autism and exposure to cocaine *in utero*. Cocaine is a neurobehavioral teratogen, as long-term monitoring of prenatally exposed children has shown deleterious effects of cocaine on their psychophysical development. Cocaine use during pregnancy can result in a wide range of adverse effects on pregnancy and its outcome.

Acta Medica Medianae 2025;64(3): 157–167.

Key words: cocaine, pregnancy, neurobehavioral teratogen, congenital anomalies

¹University of Niš, Faculty of Medicine, Department of Pathophysiology, Niš, Serbia

²University of Belgrade, Institute of the Republic of Serbia, Institute of Physics Belgrade, Belgrade, Serbia

³Health Center Surdulica, Women and Children's Health Service, Surdulica, Serbia

⁴Institute for Workers' Health Protection, Niš, Serbia

⁵University of Niš, Faculty of Medicine, doctoral studies, Niš, Serbia

Contact: Novica Bojanić
Bulevar dr Zorana Djindjica 81, 18000 Niš, Serbia
E-mail: bojanicnovica@gmail.com

Introduction

Cocaine is a local anesthetic, central nervous system stimulant and appetite suppressor. It primarily acts on the presynaptic level by blocking reuptake of monoamine neurotransmitters

dopamine, norepinephrine and serotonin through specific plasma membrane transporters. In this way, it causes tachycardia, peripheral vasoconstriction, increase in blood pressure, agitation, euphoria and excitation.

The name of this drug is derived from the word "khoka" meaning "divine tree" in the language of Inca. Cocaine is produced by extraction from evergreen leaves of *Erythroxylum coca* (Bolivian coca) and *Erythroxylum novogranatense v. truxillense* (Peruan coca), as well as other *Erythroxylum* species originating from South America. Spanish conquistadors observed in XVI century that natives could work for days and move without rest and food in the high Andes, when chewing these plants leaves (1).

Cocaine (molecular weight is 303.4) is an ester of benzoic acid and ecgonine aminoacid (methylbenzoylecgonine – C₁₇H₂₁NO₄). It is a fine, colorless or white crystalline powder with bitter taste, highly soluble in alcohol and ether (insoluble in water). Cocaine melting point is 96–98°C. About 1 kg of crude cocaine may be produced out of 150 kg of coca leaves. The end-product of coca

leaves extraction is 99% cocaine in the form of cocaine hydrochloride. It is often "cut" with other substances of similar color: starch, powder, lactosis, saccharosis, mannitol, lidocaine, procaine and amphetamine. Cocaine hydrochloride – $C_{17}H_{21}NO_4HCl$ (molecular weight is 339.8) is a fine, colorless or white, bitter tasting crystalline powder, highly soluble in water and alcohol, insoluble in ether. Its melting point is 197°C, when it begins to decompose.

From South America and Asia, cocaine is exported world-wide and illegally sold as a white powder of uncertain purity. In the street (illegal) market, cocaine is found in various concentrations (30–60%) and by different names: "c", "charlie", "coconut", "coke", "cola", "crack", "dust", "ice", "king", "lady", "lady snow", "rock(s)", "snow", "snowflake", "toot", "white", etc.

A large number of people world-wide use cocaine occasionally or regularly. About 41 million people aged ≥ 18 years reported lifetime use of cocaine, and 5.4 million people reported having used cocaine in 2019 among hospitalized patients in the United States of America (USA) (2). According to the report by the United Nations Office on Drugs and Crime, annual prevalence of cocaine use expressed as a percentage of the population in Serbia (age 15–64) was 2.0% in 2018 (3).

There are various ways to consume cocaine: orally, intranasally, sublingually, vaginally, rectally, intravenously, by inhaling smoke or rubbing it into mucosas. The slang terms for these are: chewing, draw up, sniffing, smoking, etc. Cocaine is sniffed into nostrils and absorbed through the nasal mucosa. The effects start in 3–5 minutes, and last for 30–60 minutes. Intravenous cocaine application is followed with almost immediate and much stronger effects (in 6–8 seconds) which lasts 10–15 minutes. Cocaine abuse causes severe psychological dependence. Quitting cocaine may lead to occurrence of various withdrawal symptoms: the urge for cocaine, depression, apathy, paranoia, suicidal thoughts, loss of sexual desires, insomnia, etc.

"Crack" is the street name for freebase cocaine produced by mixing powder cocaine hydrochloride with ammoniac or sodium bicarbonate and water, and later by heating it until hydrochloride evaporates. Such a substance has a form of small, wax-colored, hard blobs, and it is ready for smoking. The term "crack" is onomatopoeic, and comes from crackling that can be heard while smoking it. When smoking "crack", euphoria occurs within 10 seconds. Such a quick and powerful effect is the reason for "crack's" popularity during mid-80's of the 20th century. Psychological and physical addiction is developed quickly, sometimes already after the first dose. Long-term "crack" abuse leads to complete degradation, both psychologically (loss of self-control and self-esteem) and physically. The "crack" addict's personality is dominated by:

depression, extreme mood swings and the feeling of persecution.

In the case of simultaneous cocaine and alcohol abuse, cocaethylene is synthesized in the liver. This metabolite emphasizes euphoric effects of cocaine, but is more toxic and increases the risk of sudden death.

Cocaine addicts usually consume both cocaine and heroin. This combination is called the "speedball" because the effects of these two substances potentiate each other. This is especially dangerous because heroin takes away the unpleasant "edge" effect of cocaine, giving the addict a false sense of security. Therefore, more heroin or cocaine can be taken, which may lead to overdose and a fatal outcome.

Cocaine Effects on Gestation in Animals

Extremely low concentrations of cocaine are detected in fetal tissues after administration to pregnant mice (4). Cocaine application during organogenesis results in the increased frequency of intrauterine resorptions, as well as skeletal defects, exencephaly, eye anomalies, hydronephrosis, cryptorchism and delayed ossification of cranial bones and the bones of the paws (5). Administration of prazosin (a selective α_1 -blocker) reduces, while administration of diltiazem (a calcium channel blocker) increases the incidence of fetal anomalies in the offspring of mice exposed to cocaine *in utero* (6). In rats, during gestation, cocaine increases the possibility of resorption or fetal edema, and can also cause a significant decrease in fetal weight (7), as well as focal necrosis, necrobiosis, hemorrhages, and inflammatory reactions in the gastrointestinal tract of the embryo (8).

It has been shown that the changes that occur in rat offspring after intrauterine exposure to cocaine (bilateral necrosis and cavitation of the cerebral cortex, hemorrhage and ectopic outgrowths in the corpus striatum, vacuolization in the lens of the eye) can also be induced by temporary uterine artery occlusion, or directly by pressuring gravid uterus with fingers (9).

Intraperitoneal application of cocaine to pregnant rats during gestation causes dose-dependent development of the fetal soft tissue malformations, predominantly in the genitourinary system (10). Doses corresponding to "recreational" doses taken by humans (0.5–1.0 mg/kg) may cause the following changes in sheep during gestation: increase in maternal blood pressure (32% and 37%, respectively) and fetal blood pressure (12.6%), decrease in uterine blood flow (36% and 42%, respectively), and increase in catecholamine concentrations (210%). The maximum effect is achieved after 15 minutes, with a subsequent rapid decline (11). Prenatal cocaine exposure can have long-term dose-dependent effects on dopamine D3 receptor function in adult rhesus monkeys (12).

Cocaine Effects on Gestation in Women

Cocaine is widely distributed throughout the body after administration, and is rapidly metabolized by esterase enzymes in the circulation and in the liver. The main metabolites are benzoylecgonine, ecgonine, ecgonine methyl ester, and norcocaine, which is highly hepatotoxic. There are three different metabolic pathways of cocaine biotransformation: when hydrolyzed by hepatic and plasma esterases, benzoyl group is lost, forming ecgonine methyl ester (the most important metabolic pathway); spontaneous hydrolysis (probably non-enzymatic) leads to the formation of benzoylecgonine which is then degraded to ecgonine; and by N-demethylation forming norcocaine. Therefore, the most important metabolites of cocaine are ecgonine methyl ester, benzoylecgonine and ecgonine, all inactive metabolites. Norcocaine is an active metabolite and may have an important role in the acute poisoning with cocaine. In the presence of alcohol, cocaine undergoes a process of transesterification, forming a psychoactive metabolite, cocaethylene. This metabolite is more toxic than cocaine itself (13). There are great individual differences in cholinesterase activity, which may explain some obscurities in cocaine effects and metabolism. Plasma cholinesterase activity is significantly decreased during pregnancy (14, 15). Fetus has low plasma cholinesterase activity (14) and cocaine is metabolized very slowly in the fetus. By the end of the fourth hour after the use of cocaine, the most of the drug has already been eliminated from plasma, but metabolites (ecgonine methyl ester, benzoylecgonine and ecgonine) may still be detected even after 144 hours (16). Depending on the liver and kidney function, 1–9% of unmetabolized cocaine (there is more unmetabolized cocaine in acidic urine) and cocaine metabolites may be detected in the urine (17). Unmetabolized cocaine can also be found in saliva, and is eliminated by feces (17, 18). The placenta is no barrier to the transfer of cocaine and its pharmacologically active derivatives (norcocaine and cocaethylene) to the fetus (19). Both cocaine and benzoyl cocaine (benzoylecgonine) can still be detected in the urine of the newborn after 5 days (20).

The pharmacological effects of cocaine are associated with reduced catecholamine uptake and corresponding activation of the sympathetic nervous system. Chronic excess of circulating catecholamines in the mother who uses cocaine induces downregulation of catecholamine receptors. Vasoconstriction of the uterine and umbilical arteries causes a decrease in the delivery of oxygenated blood to the fetus, followed by hypoxemia, hypertension, and tachycardia.

The etiology of recurrent hypoxic insults to the placenta and fetus in humans lies in cocaine-induced vasoconstriction of the uterine artery (11, 21, 22). The human umbilical artery also shows intense vasoconstriction *in vitro* in the presence of

cocaine, which can be prevented by the administration of diltiazem (23). *In vitro*, the human placenta increases thromboxane synthesis and decreases prostacyclin production (24). After analysis of 69 placentas from women who used cocaine during pregnancy, its reduction (in size and weight) was evident. In addition, ablation was observed in 25% of cases, inflammation/infection (41%), ischemic changes (29%), obliteration of the intervillous space (29%), and placental membrane anomalies (16%) (25). Cocaine readily crosses the placental barrier by simple diffusion because it is highly soluble in both water and fat and has a low molecular weight. At physiological pH, cocaine is poorly ionized, but since the pH of fetal blood is lower than that of maternal blood, significantly higher concentrations of cocaine in the fetal circulation can be expected.

Cocaine and its most important metabolite benzoylecgonine have been detected in fetal brain, liver, kidneys, heart, blood and hair. The highest concentrations were found in the liver (as for cocaine), and the brain (as for benzoylecgonine) (26). The cocaine plasma half-life is around 30 to 90 min, but metabolites are present in the urine for a longer period (2 to 5 days). After intravenous application, cocaine elimination half-time is 30–40 minutes, but its metabolites may be detected even after more than a week. Elimination half-time of benzoylecgonine with newborns is 14.6 hours, twice as long as with adults (27). In one case of a mother's severe poisoning, the concentration of this metabolite measured in the newborn, was 41 000 ng/ml (27).

The prevalence of cocaine use during pregnancy varies worldwide. The percentage established were 4.4% (of 353 newborn meconium samples tested) in Barcelona (Spain) (28), 5.3% (of 1625 pregnant women tested) in Toronto, Canada (29), 11.5% (of 1111 anonymous postnatal maternal urine samples from New York (USA) (30). An alarmingly high 13.6% of newborns (966 of 7083 consecutive births) were reported to have suffered from intrauterine cocaine exposure in Oakland, California (31).

Long-term use cocaine during pregnancy causes (21, 30–128): intrauterine growth retardation (21, 30, 38–41, 45, 49, 54, 56, 58, 63, 75–80, 86, 87, 90, 108, 110, 120), abruptio of placenta (26, 33, 34, 49, 54, 63, 74–77, 89), increased frequency of premature birth (21, 30, 33, 34, 42, 49, 54, 56, 59, 63, 76, 87, 90), premature rupture of the membranes (36, 59, 63, 91, 101), precipitous labor (21, 63), meconium-stained amniotic fluid (63), stillbirth (37, 76), neonatal necrotizing enterocolitis (43, 70, 71, 81, 113), neonatal bowel perforation (56, 80, 82, 112), complete bilateral absence of the diaphragm (105), neonatal respiratory disorders (50), neonatal subcutaneous fat necrosis (102), sudden infant death syndrome (31, 34, 37, 94), intimal fibromuscular dysplasia of numerous blood vessels (122), hearing impairment (46, 119), retinal

hemorrhages (114, 115), fetal or maternal intracranial accident (36, 44, 48, 49, 57, 69, 90, 103, 109, 126), rupture of the uterus (57, 95, 111, 125), ruptured tubal ectopic pregnancy (55), placenta previa (76, 107, 115), changes in neonatal behavior (34, 53, 76, 98), neonatal cardiac arrhythmias (36, 51, 56, 100, 127), various congenital anomalies (32, 34, 35, 38, 41, 52, 56, 62, 64–68, 72, 73, 80, 83–86, 89–94, 96–99, 117–121), and maternal myocardial infarction (104, 105, 123, 129).

Retrospective studies have shown that intrauterine exposure to cocaine causes major malformations in newborns with a risk of 8–10% (37, 38). Some authors have linked the increasing number of women and men using cocaine occasionally or regularly to an increase in the incidence of congenital heart defects (32, 51). Cocaine exposure can lead to the development of congenital cardiovascular (38, 56, 65–68, 89, 91, 94, 120), genitourinary (34, 35, 41, 49, 53, 65, 67, 83, 92, 99, 119), brain and skull anomalies (32, 64, 83, 96–98, 117), and absence of limbs (73, 83, 85, 86, 116, 117). Interestingly, the incidence of ankyloglossia in newborns is 3.5 times higher in those exposed prenatally to cocaine (80). A case of a newborn with hypothalamic hamartoblastoma, postaxial polydactyly in both hands and the left foot, and heart defects (Pallister-Hall syndrome) after intrauterine exposure to cocaine, marijuana, and methaqualone has been reported (32). The development of Poland-Möbius syndrome with calcifications in the medulla oblongata and unilateral defects of the right pectoral muscle, thorax, and hand has been described in a newborn exposed to cocaine during the first trimester of gestation. In addition, central apnea, bilateral cranial nerve palsies, and dysphagia have been reported after birth (130).

Cocaine has been shown to induce bilirubin metabolic pathways, thereby reducing the risk of hyperbilirubinemia in neonates. Bilirubin concentrations in neonates exposed to cocaine *in utero* are half that of controls ($55 \pm 26 \mu\text{mol/L}$ vs. $110 \pm 32 \mu\text{mol/L}$) (131).

After birth, neonates exposed to cocaine *in utero* may exhibit the following signs: jittery/tremor, high pitched cry, irritability, excessive suck, hyperalertness and autonomic instability (124).

During the first days of a newborn, minute volume and stroke heart volume are decreased, while mean arterial pressure is increased (132). Hypertension or borderline hypertension was observed in 6 of 12 children exposed prenatally to cocaine, without any renal, cardiovascular, or endocrine abnormalities (133).

Mechanism of Action of Cocaine on Fetus

Cocaine impairs neurotransmission in the central nervous system during embryonic

development, especially in the first trimester. It can therefore be considered a neurobehavioral teratogen for humans (49). These changes most likely occur in the central dopaminergic system of infants exposed to cocaine *in utero*, since concentrations of homovanillic acid (a major metabolite of dopamine) are significantly reduced in the cerebrospinal fluid (134). High concentrations of the circulating catecholamine precursor dihydroxyphenylalanine, and consequently increased catecholamine activity, have also been found in children exposed prenatally to cocaine. These changes may play an important role in the pathogenesis of neurobehavioral disorders (78).

The pathogenesis of these impairments at the cellular level includes dysfunctional myelination, disrupted dendritic architecture, and synaptic alterations. Prenatal exposure to cocaine is also associated with disruption of the hypothalamic-pituitary-adrenal axis hormones that mediate neuroendocrine responses (135).

Children exposed prenatally to cocaine have shown specific language and cognitive deficits, and impaired social development (136, 137). There is also a significant depression of organizational responses to external stimuli according to the Brazelton scale in such children (34, 37), as well as transient electroencephalographic abnormalities (138). Exposed children have a 2.8 times higher risk of showing learning difficulties, compared with unexposed children (139). Prenatal cocaine exposure slows postnatal growth at seven and ten years of age (140) and predicts poorer perceptual reasoning IQ at the age of nine (141).

In a long-term follow-up study of 70 children exposed to cocaine *in utero*, a number of significant neurodevelopmental abnormalities were reported: delayed speech (94%) and an extremely high incidence of autism (11.4%) (79). The authors suggest that the high incidence of autism is specific to intrauterine cocaine exposure, as it is not observed in those exposed to other opiates or alcohol. They also described various optical anomalies in children exposed to cocaine *in utero* (142, 143): frequent refractive errors, optic nerve anomalies, microphthalmia, development of retinopathy, and prolonged eyelid edema. At age 21, young adults who were prenatally exposed to cocaine had lower mean full-scale (83.7 ± 10.4 vs. 87.3 ± 12.5 , $p < 0.1$) and perceptual reasoning IQ (87.3 ± 11.5 vs. 91.4 ± 13.9 , $p < 0.02$), lower high school completion rates (75% vs. 86%, $p < 0.02$), and were slightly more likely to have been on probation than non-cocaine exposed young adults, but did not differ in Verbal IQ, self-reported problematic substance use or incarceration. Young adults with prenatal cocaine exposed in foster/adoptive had similar lower IQ scores but had better verbal skills and high school graduation rates that did not differ from non-cocaine exposed young adults (80.6 vs 86.2%, $p > .05$) (144).

In 1985–1986, the cost of postpartum care in the United States was 5,200\$ higher for newborns prenatally exposed to cocaine than for babies who were not. The increased cost was primarily due to longer hospital stays (by an average of four days), admissions to special care units, and various medical procedures and therapies, among other factors (145). In another study, data showed that intrauterine exposure to cocaine or some other illicit drug in 1991–1992 increased hospital stay by seven days and increased costs by \$7,731 compared to controls (146). The United States spends about \$500 million annually to address this growing and serious problem (1991 data), which means that about 100,000 newborns are exposed to cocaine *in utero* annually (145).

Exposure to cocaine during the development of the nervous system can lead to permanent changes in brain structure and function and later produce altered responses to environmental or pharmacological challenges (147). Cocaine use during pregnancy has been associated with a higher risk of heart failure 10 years later (148) and may be associated with a risk of cerebrovascular disease and cerebrovascular interventions more than 15 years later (149).

Cocaine exposure during nervous system development can lead to lasting changes in brain structure and function, resulting in altered responses to environmental or pharmacological challenges later in life (147).

Numerous studies suggest that cocaine causes changes in the fetus, which can vary significantly in intensity and frequency, depending on the amount of cocaine used, duration and timing of exposure during pregnancy, potential interactions with other drugs (e.g., alcohol), habits, as well as the possibility of obtaining and introducing cocaine into the pregnant woman's body.

The identification of “fetal cocaine syndrome” was not possible until recently, unlike the identification of “fetal alcohol syndrome” and “fetal hydantoin syndrome”. However, attempts have been made, and the most comprehensive description of fetal cocaine syndrome to date includes the following: neurological irritability, large fontanelles, prominent glabella, marked periorbital and palpebral edema, low nasal bridge with a transverse crease, short nose, lateral soft tissue nasal build-up and small toenails (90).

Conclusion

Cocaine use during pregnancy may have deleterious effects on both pregnancy and its outcome. It has been suggested that cocaine abuse causes: intrauterine growth retardation with low birth weight and microcephaly, placental ablation, increased frequency of premature delivery, premature rupture of the membranes, stillbirth, neonatal necrotizing enterocolitis, neonatal bowel perforation, neonatal respiratory disorders, neonatal subcutaneous fat necrosis, sudden infant death syndrome, fetal or maternal intracranial accident, ruptured tubal ectopic pregnancy, placenta previa, changes in neonatal behavior, neonatal cardiac arrhythmias, maternal myocardial infarction and various congenital anomalies. It has not been proven that these effects depend on the dose used, the time of exposure, and the simultaneous use of other drugs with cocaine. Some authors suggest that there is a specific fetal cocaine syndrome and a link between the high incidence of autism and exposure to cocaine *in utero*. Cocaine is a neurobehavioral teratogen, as long-term monitoring of prenatally exposed children has shown deleterious effects of cocaine on their psychophysical development.

References

- Biondich AS, Joslin JD. Coca: The history and medical significance of an ancient Andean tradition. *Emerg Med Int* 2016;2016:4048764. [\[CrossRef\]](#) [\[PubMed\]](#)
- Gangu K, Bobba A, Basida SD, Avula S, Chela H, Singh S. Trends of cocaine use and manifestations in hospitalized patients: a cross-sectional study. *Cureus* 2022;14(2):e22090. [\[CrossRef\]](#) [\[PubMed\]](#)
- Prevalence of drug use in the general population, including NPS – national data. <https://www.unodc.org/unodc/en/data-and-analysis/wdr2024-annex.html>
- Shah NS, May DA, Yates JD. Disposition of levo-(3H)-cocaine in pregnant and nonpregnant mice. *Toxicol Appl Pharmacol* 1980;53:279-84. [\[CrossRef\]](#) [\[PubMed\]](#)
- Mahalik MP, Gautieri RF, Mann DE Jr. Teratogenic potential of cocaine hydrochloride in CF-1 mice. *J Pharm Sci* 1980;69:703-6. [\[CrossRef\]](#) [\[PubMed\]](#)
- Mahalik MP, Hitner HW. Antagonism of cocaine-induced fetal anomalies by prazosin and diltiazem in mice. *Reprod Toxicol* 1992;6(2):161-9. [\[CrossRef\]](#) [\[PubMed\]](#)
- Fantel AG, Macphail BJ. The teratogenicity of cocaine. *Teratology* 1982;26(1):17-9. [\[CrossRef\]](#) [\[PubMed\]](#)
- Buyukunal C, Kilic N, Dervisoglu S, Altug T. Maternal cocaine abuse resulting in necrotizing enterocolitis – an experimental study in a rat model. *Acta Paediatr* 1994;Suppl 396:91-3. [\[CrossRef\]](#) [\[PubMed\]](#)
- Webster WS, Brown-Woodman PD, Lipson AH, Ritchie HE. Fetal brain damage in the rat following prenatal exposure to cocaine. *Neurotoxicol Teratol* 1991;13(6):621-6. [\[CrossRef\]](#) [\[PubMed\]](#)
- el-Bizri H, Guest I, Varma DR. Effects of cocaine on rat embryo development in vivo and in cultures. *Pediatr Res* 1991;29:187-90. [\[CrossRef\]](#) [\[PubMed\]](#)
- Moore T, Sorg J, Miller L, Key TC, Resnik R. Hemodynamic effects of intravenous cocaine on the pregnant ewe and fetus. *Am J Obstet Gynecol* 1986;155(4):883-8. [\[CrossRef\]](#) [\[PubMed\]](#)
- Hamilton LR, Czoty PW, Gage HD, Nader MA. Characterization of the dopamine receptor system in adult rhesus monkeys exposed to cocaine throughout gestation. *Psychopharmacology* 2010;210(4):481-8. <https://pmc.ncbi.nlm.nih.gov/articles/PMC2878372/pdf/nihms195737.pdf>
- Roy S, Konala VM, Adapa S, Naramala S, Bose S. Cocaine and Alcohol Co-Ingestion-Induced Severe Rhabdomyolysis With Acute Kidney Injury Culminating in Hemodialysis-Dependent End-Stage Renal Disease: A Case Report and Literature Review. *Cureus*. 2020 Jun 13;12(6):e8595. <https://pmc.ncbi.nlm.nih.gov/articles/PMC7362596/>
- Pritchard JA. Plasma cholinesterase activity in normal pregnancy and in eclamptogenic toxemias. *South Am J Obstet Gynecol* 1955;70(5):1083-6. [\[CrossRef\]](#) [\[PubMed\]](#)
- Fleming JA, Byck R, Barash PG. Pharmacology and therapeutic applications of cocaine. *Anesthesiology* 1990;73(3):518-31. [\[CrossRef\]](#) [\[PubMed\]](#)
- Ellenhorn MJ, Barceloux DG. Cocaine. In Ellenhorn MJ, Barceloux DG eds. *Medical toxicology: diagnosis and treatment of human poisoning*. New York, Elsevier Science Publishing Company, Inc, 1988: 644-61.
- Clarke EGC. Clarke's isolation and identification of drugs in pharmaceuticals, body fluids, and post-mortem materials, 2nd ed., London, The Pharmaceutical Press, 1986.
- Cone EJ, Weddington WW. Prolonged occurrence of cocaine in human saliva and urine after chronic use. *J Anal Toxicol* 1989;13(2):65-8. [\[CrossRef\]](#) [\[PubMed\]](#)
- Schenker S, Yang Y, Johnson RF, Downing JW, Schenken RS, Henderson GI, King TS. The transfer of cocaine and its metabolites across the term human placenta. *Clin Pharm Ther* 1993;53(3):329-39. [\[CrossRef\]](#) [\[PubMed\]](#)
- Chasnoff IJ, Lewis DE, Griffith DR, Willey S. Cocaine and pregnancy: clinical and toxicological implications for the neonate. *Clin Chem* 1989;35(7):1276-8. [\[CrossRef\]](#) [\[PubMed\]](#)
- MacGregor SN, Keith LG, Chasnoff IJ, Rosner MA, Chisum GM, Shaw P, et al. Cocaine during pregnancy: adverse perinatal outcome. *Am J Obstet Gynecol* 1987;157(3):686-90. [\[CrossRef\]](#) [\[PubMed\]](#)
- Woods JR, Plessinger MA, Clark KE. Effects of cocaine on uterine blood flow and fetal oxygenation. *JAMA* 1987;257(7):957-61. [\[CrossRef\]](#) [\[PubMed\]](#)
- Chokshi SK, Gal D, Whelton JA, Isner JM. Evidence that fetal distress in newborn of cocaine users is due to vascular spasm and may be attenuated by pretreatment with diltiazem (Abstract). *Circulation* 1989;80:II-185.
- Monga M, Chmielowiec S, Andres RL, Troyer, LR, Parisi VM. Cocaine alters placental production of thromboxane and prostacyclin. *Am J Obstet Gynecol* 1994;171(4):965-9. [\[CrossRef\]](#) [\[PubMed\]](#)
- Yasin SY, Burkett G, Palow D, Abuhamad A. Placentas of cocaine addicted mothers (Abstract). *Am J Obstet Gynecol* 1991;164:290. [\[CrossRef\]](#)
- Klein J, Greenwald M, Becker L, Koren G. Fetal distribution of cocaine: case analysis. *Pediatr Pathol* 1992;12(3):463. [\[CrossRef\]](#) [\[PubMed\]](#)
- Dempsey D, Jacob III P, Partridge JC, Jones RT, Panganiban K, Rowbotham MC. Cocaine metabolite kinetics in the newborn. *J Anal Toxicol* 1999;23(1):24-8.
- Garcia-Algar O, Kulaga V, Gareri J, Koren G, Vall O, Zuccaro P, et al. Alarming prevalence of fetal alcohol exposure in a Mediterranean city. *Ther Drug Monit* 2008;30(2):249-54. [\[CrossRef\]](#) [\[PubMed\]](#)
- Graham K, Koren G. Characteristics of pregnant women exposed to cocaine in Toronto between 1985 and 1990. *Can Med Assoc J* 1991;144(5):563-8. [\[PubMed\]](#)

30. McCalla S, Minkoff HL, Feldman J, Delke I, Salwin M, Valencia G, et al. The biologic and social consequences of perinatal cocaine use in an inner-city population: results of an anonymous cross-sectional study. *Am J Obstet Gynecol* 1991;164:625-31. [\[CrossRef\]](#) [\[PubMed\]](#)
31. Durand DJ, Espinoza AM, Nickerson BG. Association between prenatal cocaine exposure and sudden infant death syndrome. *Am J Obstet Gynecol* 1990;117(6):909-11. [\[CrossRef\]](#) [\[PubMed\]](#)
32. Huff DS, Fernandes M. Two cases of congenital hypothalamic hamartoblastoma, polydactyly and other congenital anomalies (Pallister-Hall syndrome) *N Eng J Med* 1982;306(7):430-1. [\[CrossRef\]](#) [\[PubMed\]](#)
33. Acker D, Sachs BP, Tracey KJ, Wise WE. Abruptio placentae associated with cocaine use. *Am J Obstet Gynecol* 1983;146(2):220-1. [\[CrossRef\]](#) [\[PubMed\]](#)
34. Chasnoff IJ, Burns WJ, Schnoll SH, Burns KA. Cocaine use in pregnancy. *N Eng J Med* 1985;313(11):666-9. [\[CrossRef\]](#) [\[PubMed\]](#)
35. Bingol N, Fuchs M, Holipas N, Henriquez R, Pagan M, Diaz V. Prune belly syndrome associated with maternal cocaine abuse. *Am J Hum Genet* 1986;39:147A.
36. Chasnoff IJ, Bussey ME, Savich R, Stack CM. Perinatal cerebral infarction and maternal cocaine use. *J Pediatr* 1986;108(3):456-9. [\[CrossRef\]](#) [\[PubMed\]](#)
37. Chasnoff IJ, Burns KA, Burns WJ. Cocaine use in pregnancy: perinatal morbidity and mortality. *Neurotoxicol Teratol* 1987;9(4):291-5. [\[CrossRef\]](#) [\[PubMed\]](#)
38. Bingol N, Fuchs M, Diaz V, Stone RK, Gromisch DS. Teratogenicity of cocaine in humans. *J Pediatr* 1987;110(1):93-6. [\[CrossRef\]](#) [\[PubMed\]](#)
39. Oro AS, Dixon SD. Perinatal cocaine and methamphetamine exposure: maternal and neonatal correlates. *J Pediatr* 1987;111(4):571-8. [\[CrossRef\]](#) [\[PubMed\]](#)
40. Ryan L, Ehrlich S, Finnegan L. Cocaine abuse in pregnancy: effects on the fetus and newborn. *Neurotoxicol Teratol* 1987;9(4):295-9. [\[CrossRef\]](#) [\[PubMed\]](#)
41. Chasnoff IJ, Chisum GM, Kaplan WE. Maternal cocaine use and genitourinary tract malformation. *Teratology* 1988;37(3):201-4. [\[CrossRef\]](#) [\[PubMed\]](#)
42. Chouteau M, Namerow PB, Leppert P. The effect of cocaine abuse on birth weight and gestational age. *Obstet Gynecol* 1988;72(3 Pt 1):351-4. [\[PubMed\]](#)
43. Telsey AM, Merritt TA, Dixon SD. Cocaine exposure in a term neonate: necrotizing enterocolitis as a complication. *Clin Pediatr* 1988;27(11):547-50. [\[CrossRef\]](#) [\[PubMed\]](#)
44. Tenorio GM, Nazvi M, Bickers GH, Hubbard RH. Intrauterine stroke and maternal polydrug abuse. *Clin Pediatr* 1988;27(11):565-7. [\[CrossRef\]](#) [\[PubMed\]](#)
45. Cherukuri R, Minkoff H, Feldman J, Parekh A, Glass L. A cohort study of alkaloidal cocaine (crack) in pregnancy. *Obstet Gynecol* 1988;72(2):147-51. [\[PubMed\]](#)
46. Shih L, Cone-Wesson B, Reddix B. Effects of maternal cocaine abuse on the neonatal auditory system. *Int J Pediatr Otorhinolaryngol* 1988;15(3):245-51. [\[CrossRef\]](#) [\[PubMed\]](#)
47. Zuckerman B, Frank DA, Hingson R, Amaro H, Levenson SM, Kayne H, et al. Effects of maternal marijuana and cocaine use on fetal growth. *N Eng J Med* 1989;320(12):762-8. [\[CrossRef\]](#) [\[PubMed\]](#)
48. Dixon S, Bejar R. Echoencephalographic findings in neonates associated with maternal cocaine and methamphetamine use: incidence and clinical correlates. *J Pediatr* 1989;115(5 Pt 1):770-8. [\[CrossRef\]](#) [\[PubMed\]](#)
49. Chasnoff IJ, Griffith DR, MacGregor S, Dirkes K, Burns KA. Temporal patterns of cocaine use in pregnancy. *JAMA* 1989;261(12):1741-4. [\[CrossRef\]](#) [\[PubMed\]](#)
50. Chasnoff IJ, Hunt CE, Kletter R, Kaplan D. Prenatal cocaine exposure is associated with respiratory pattern abnormalities. *Am J Dis Child* 1989;143(5):583-7. [\[CrossRef\]](#) [\[PubMed\]](#)
51. Geggel RL, McInerney J, Estes NAM III. Transient neonatal ventricular tachycardia associated with maternal cocaine use. *Am J Cardiol* 1989;63(5):383-4. [\[CrossRef\]](#) [\[PubMed\]](#)
52. Chavez GF, Mulinare J, Cordero JF. Maternal cocaine use during early pregnancy as a risk factor for congenital urogenital anomalies. *JAMA* 1989;262(6):795-8. [\[CrossRef\]](#) [\[PubMed\]](#)
53. Hume RF, O'Donnell KJ, Stanger CL, Killam AP, Gingras JL. In utero cocaine exposure: observation of fetal behavioral state may predict neonatal outcome. *Am J Obstet Gynecol* 1989;161(3):685-90. [\[CrossRef\]](#) [\[PubMed\]](#)
54. Keith LG, MacGregor S, Friedell S, Rosner M, Chasnoff IJ, Sciarr JJ. Substance abuse in pregnant women: recent experience at the Perinatal center for chemical dependence of Northwestern memorial hospital. *Obstet Gynecol* 1989;73(5 Pt 1):715-20. [\[CrossRef\]](#) [\[PubMed\]](#)
55. Thatcher SS, Corfman R, Grosso J, Silverman DG, DeCherney AH. Cocaine use and acute rupture of ectopic pregnancies. *Obstet Gynecol* 1989;74(3 Pt 2):478-9. [\[PubMed\]](#)
56. Little BB, Snell LM, Klein VR, Gilstrap LC III. Cocaine abuse during pregnancy: maternal and fetal implications. *Obstet Gynecol* 1989;73(2):157-60. [\[PubMed\]](#)
57. Mercado A, Johnson G Jr, Calver D, Sokol RJ. Cocaine, pregnancy and postpartum intracerebral hemorrhage. *Obstet Gynecol* 1989;73(3 Pt 2):467-8. [\[PubMed\]](#)
58. Hadeed AJ, Siegel SR. Maternal cocaine use during pregnancy: effect on the newborn infant. *Pediatrics* 1989;84(2):205-10. [\[CrossRef\]](#) [\[PubMed\]](#)
59. Neerhof MG, MacGregor SN, Retzky SS, Sullivan TP. Cocaine abuse during pregnancy: peripartum prevalence and perinatal outcome. *Am J Obstet Gynecol* 1989;161(3):633-8. [\[CrossRef\]](#) [\[PubMed\]](#)
60. s;85:767-9.
61. Gonsoulin W, Borge D, Moise KJ Jr. Rupture of unscarred uterus in primigravid woman in association with cocaine abuse. *Am J Obstet Gynecol* 1990;163(2):526-7. [\[CrossRef\]](#) [\[PubMed\]](#)
62. Hoyme HE, Jones KL, Dixon SD, Jewett T, Hanson JW, Robinson LK et al. Prenatal cocaine exposure and fetal vascular disruption. *Pediatrics* 1990;85(5):743-7. [\[CrossRef\]](#) [\[PubMed\]](#)
63. Mastrogiannis DS, Decavalas GO, Verma U, Tejani N. Perinatal outcome after recent cocaine usage. *Obstet Gynecol* 1990;76(1):8-11. [\[PubMed\]](#)
64. Rais Bahrami K, Naqvi M. Hydranencephaly and maternal cocaine use: a case report. *Clin Pediatr Phila* 1990;29(12):729-30. [\[CrossRef\]](#) [\[PubMed\]](#)
65. Rosenstein BJ, Wheeler JS, Heid PL. Congenital renal abnormalities in infants with in utero cocaine

- exposure. J Urol 1990;144(1):110-2. [\[CrossRef\]](#) [\[PubMed\]](#)
66. Little BB, Snell LM. Cocaine use during pregnancy and congenital anomalies: further study (Abstract). Am J Obstet Gynecol 1991;164:350A. [\[CrossRef\]](#)
 67. Lipshultz SE, Frassica JJ, Orav J. Cardiovascular abnormalities in infants prenatally exposed to cocaine. J Pediatr 1991;118(1):44-51. [\[CrossRef\]](#) [\[PubMed\]](#)
 68. Shaw GM, Malcoe LH, Lammer EJ, Swan SH. Maternal use of cocaine during pregnancy and congenital cardiac anomalies. J Pediatr 1991;118(1):167-8. [\[CrossRef\]](#) [\[PubMed\]](#)
 69. Kapur RP, Shaw CM, Shepard TH. Brain hemorrhages in cocaine-exposed human fetuses. Teratology 1991;44(1):11-8. [\[CrossRef\]](#) [\[PubMed\]](#)
 70. Downing GJ, Horner SR, Kilbride HW. Characteristics of perinatal cocaine-exposed infants with necrotizing enterocolitis. Am J Dis Child 1991;145(1):26-7. [\[CrossRef\]](#) [\[PubMed\]](#)
 71. Czyrko C, Del Pin CA, O'Neill JAJr, Peckham GJ, Ross AJ. Maternal cocaine abuse and necrotizing enterocolitis: outcome and survival. J Pediatr Surg 1991;26(4):414-8. [\[CrossRef\]](#) [\[PubMed\]](#)
 72. Dominguez R, Vila Coro AA, Slopis JM, Bohan TP. Brain and ocular abnormalities in infants with in utero exposure to cocaine and other street drugs. Am J Dis Child 1991;145(6):688-95. [\[CrossRef\]](#) [\[PubMed\]](#)
 73. Hanning VL, Philips JA III. Maternal cocaine abuse and fetal anomalies: evidence for teratogenic effects of cocaine. South Med J 1991;84(4):498-9. [\[CrossRef\]](#) [\[PubMed\]](#)
 74. Dombrowski MP, Wolfe HM, Welch RA, Evans MI, Little BB, Snell LM et al. Cocaine abuse is associated with abruptio placentae and decreased birth weight, but not shorter labor. Obstet Gynecol 1991;77(1):139-41. [\[PubMed\]](#)
 75. Thorp JM Jr. Cocaine abuse is associated with abruptio placentae and decreased birth weight, but not shorter labor. Obstet Gynecol 1991;77(5):807-8. [\[PubMed\]](#)
 76. Handler A, Kistin N, Davis F, Ferre C. Cocaine use during pregnancy: perinatal outcomes. Am J Epidemiol 1991;133(8):818-25. [\[CrossRef\]](#) [\[PubMed\]](#)
 77. Ansari AZ, Al Sayed A, Patibandla S, Kumar S, Patibandla L, Ali R. Emergency hysterectomy following placental abruption in a patient with a history of substance abuse: A case report. Cureus 2024;16(4):e57997. [\[CrossRef\]](#) [\[PubMed\]](#)
 78. Mirochnick M, Meyer J, Cole J, Herren T, Zuckerman B. Circulating catecholamine concentrations in cocaine-exposed neonates: a pilot study. Pediatrics 1991;88(3):481-5. [\[CrossRef\]](#) [\[PubMed\]](#)
 79. Davis E, Fennoy I, Laraque D, Kamen N, Brown G, Mitchell J. Autism and developmental abnormalities in children with perinatal cocaine exposure. J Nat Med Assoc 1992;84(4):315-9. [\[PubMed\]](#)
 80. Harris EF, Friend GW, Tolley EA. Enhanced prevalence of ankyloglossia with maternal cocaine use. Cleft Palate Craniofac J 1992;29(1):72-6. [\[CrossRef\]](#) [\[PubMed\]](#)
 81. Czyrko C, Del Pin CA, O'Neill JA Jr, Peckham GJ, Ross AJ 3rd. Maternal cocaine abuse and necrotizing enterocolitis: outcome and survival. J Pediatr Surg 1991;26(4):414-8; discussion 419-21. [https://www.jpedsurg.org/article/0022-3468\(91\)90988-6/pdf](https://www.jpedsurg.org/article/0022-3468(91)90988-6/pdf)
 82. Hall TR, Zaninovic A, Lewin D, Barret C, Boechat MI. Neonatal intestinal ischemia with bowel perforation: an in utero complication of maternal cocaine abuse. Am J Roentgenol 1992;158(6):1303-4. [\[CrossRef\]](#) [\[PubMed\]](#)
 83. Martin ML, Khoury MJ, Cordero JF, Waters GD. Trends in rates of multiple vascular disruption defects, Atlanta, 1968-1989: is there evidence of a cocaine teratogenic epidemic? Teratology 1992;45(6):647-53. [\[CrossRef\]](#) [\[PubMed\]](#)
 84. Viscarello RR, Ferguson DD, Nores J, Hobbins JC. Limb-body wall complex associated with cocaine abuse: further evidence of cocaine's teratogenicity. Obstet Gynecol 1992;80(3 Pt 2):523-6. [\[PubMed\]](#)
 85. Sheinbaum KA, Badell A. Psychiatric management of two neonates with limb deficiencies and prenatal cocaine exposure. Arch Phys Med Rehabil 1992;73(4):385-8. [\[CrossRef\]](#) [\[PubMed\]](#)
 86. Sarpong S, Headings V. Sirenomelia accompanying exposure of the embryo to cocaine. South Med J 1992;85(5):545-7. [\[CrossRef\]](#) [\[PubMed\]](#)
 87. Hawthorne JL, Maier RC. Drug abuse in obstetric population of a midsized city. South Med J 1993;86(12):1334-8. [\[CrossRef\]](#) [\[PubMed\]](#)
 88. Bateman DA, Ng SK, Hansen CA, Heagarty MC. The effects of intrauterine cocaine exposure in newborns. Am J Public Health 1993;83(2):190-3. [\[CrossRef\]](#) [\[PubMed\]](#)
 89. Dusick AM, Covert RF, Schreiber MD et al. Risk of intracranial hemorrhage and other adverse outcomes after cocaine exposure in a cohort of 323 very low birth weight infants. J Pediatr 1993;122(3):438-45. [\[CrossRef\]](#) [\[PubMed\]](#)
 90. Fries MH, Kuller JA, Norton ME, Yankowitz J, Kobori J, Good WV, et al. Facial features of infant exposed prenatally to cocaine. Teratology 1993;48(5):413-20. [\[CrossRef\]](#) [\[PubMed\]](#)
 91. Martinez JM, Fortuny A, Comas C, Puerto B, Borell A, Palacio M et al. Body stalk anomaly associated with maternal cocaine abuse. Prenat Diagn 1994;14(8):669-72. [\[CrossRef\]](#) [\[PubMed\]](#)
 92. Battin M, Albersheim S, Newman D, Lewis P. Congenital genitourinary tract abnormalities following cocaine exposure in utero (Abstract). Clin Invest Med 1994;17:29A. [\[CrossRef\]](#) [\[PubMed\]](#)
 93. Robin NH, Zackai EH. Unusual craniofacial dysmorphism due to prenatal alcohol and cocaine exposure. Teratology 1994;50(2):160-4. [\[CrossRef\]](#) [\[PubMed\]](#)
 94. Jasnosz KM, Hermansen MC, Snider C, Sang K. Congenital complete absence (bilateral agenesis) of the diaphragm: a rare variant of congenital diaphragmatic hernia. Am J Perinatol 1994;11(5):340-3. [\[CrossRef\]](#) [\[PubMed\]](#)
 95. Iriye BK, Bristow RE, Hsu CD, Bruni R, Johnson TR. Uterine rupture associated with recent antepartum cocaine abuse. Obstet Gynecol 1994;83(5 Pt 2):840-1. [\[PubMed\]](#)
 96. Gomez-Anson B, Ramsey RG. Pachygyria in a neonate with prenatal cocaine exposure: MR features. J Comput Assist Tomogr 1994;18(4):637-9. [\[CrossRef\]](#) [\[PubMed\]](#)
 97. Suchet IB. Schizencephaly: antenatal and postnatal assesment with colour-flow Doppler imaging. Can Assoc Radiol J 1994;45:193-200. [\[PubMed\]](#)
 98. Gieron-Korthals MA, Helal A, Martinez CR. Expanding spectrum of cocaine induced central nervous system malformations. Brain Dev 1994;16(3):253-6. [\[CrossRef\]](#) [\[PubMed\]](#)

99. Lezcano L, Antia DE, Sahdev S, Jhaveri M. Crossed renal ectopia associated with maternal alkaloid cocaine abuse: a case report. *J Perinatol* 1994;14(3):230-3. [\[PubMed\]](#)
100. Frassica JJ, Orav EJ, Walsh EP, Lipshultz SE. Arrhythmias in children prenatally exposed to cocaine. *Arch Pediatr Adolesc Med* 1994;148(11):1163-9. [\[CrossRef\]](#) [\[PubMed\]](#)
101. Dinsmoor MJ, Irons SJ, Christmas JT. Preterm rupture of the membranes associated with recent cocaine use. *Am J Obstet Gynecol* 1994;171(2):305-8. [\[CrossRef\]](#) [\[PubMed\]](#)
102. Carraccio C, Papadimitriou J, Feinberg P. Subkutaneous fat necrosis of the newborn: link to maternal use of cocaine during pregnancy. *Clin Pediatr Phila* 1994;33(5):317-8. [\[CrossRef\]](#) [\[PubMed\]](#)
103. Singer LT, Yamashita TS, Hawkins S, Cairns D, Baley J, Kliegman R. Increased incidence of intraventricular hemorrhage and developmental delay in cocaine-exposed, very low birth weight infants. *J Pediatr* 1994;124(5 Pt 1):765-71. [\[CrossRef\]](#) [\[PubMed\]](#)
104. Bulbul ZR, Rosenthal DN, Kleinman CS. Myocardial infarction in the perinatal period secondary to maternal cocaine abuse. *Arch Pediatr Adolesc Med* 1994;148(10):1092-6. [\[CrossRef\]](#) [\[PubMed\]](#)
105. Jasnosz KM, Hermansen MC, Snider C, Sang K. Congenital complete absence (bilateral agenesis) of the diaphragm: a rare variant of congenital diaphragmatic hernia. *Am J Perinatol* 1994;11(5):340-3. [\[CrossRef\]](#) [\[PubMed\]](#)
106. Livingston JC, Mabie BC, Ramanathan J. Crack cocaine, myocardial infarction, and troponin I levels at the time of cesarean delivery. *Anesth Analg* 2000;91(4):913-5. [\[CrossRef\]](#) [\[PubMed\]](#)
107. Handler AS, Mason ED, Rosenberg DL, Davis FG. The relationship between exposure during pregnancy to cigarette smoking and cocaine use and placenta previa. *Am J Obstet Gynecol* 1994;170(3):884-9. [\[CrossRef\]](#) [\[PubMed\]](#)
108. Mirochnick M, Frank DA, Cabral H, et al. Relation between meconium concentration of the cocaine metabolite benzoylecgonine and fetal growth. *J Pediatr* 1995;126:636-8. [\[CrossRef\]](#) [\[PubMed\]](#)
109. Iriye BK, Asrat T, Adashek JA, Carr MH. Intraventricular haemorrhage and maternal brain death associated with antepartum cocaine abuse. *Br J Obstet Gynaecol* 1995;102(1):68-9. [\[CrossRef\]](#) [\[PubMed\]](#)
110. Chazotte C, Youchah J, Freda MC. Cocaine using during pregnancy and low birth weight: the impact of prenatal care and drug treatment. *Semin Perinatol* 1995;19(4):293-300. [\[CrossRef\]](#) [\[PubMed\]](#)
111. Mishra A, Landzberg BR, Parente JT. Uterine rupture in association with alkaloidal ("crack") cocaine abuse. *Am J Obstet Gynecol* 1995;173(1):243-4. [\[CrossRef\]](#) [\[PubMed\]](#)
112. The' TG, Young M, Rosser S. In-utero cocaine exposure and neonatal intestinal perforation: a case report. *J Natl Med Assoc* 1995;87(12):889-91. [\[PubMed\]](#)
113. Lopez SI, Tausch HW, Findlay RD, Walther FJ. Time of onset of necrotizing enterocolitis in newborn infants with known prenatal cocaine exposure. *Clin Pediatr Phila* 1995;34(8):424-9. [\[CrossRef\]](#) [\[PubMed\]](#)
114. Silva-Araujo AL, Tavares MA, Patacao MH, Carolino RM. Retinal hemorrhages associated with in utero exposure to cocaine: experimental and clinical findings. *Retina* 1996;16(5):411-8. [\[CrossRef\]](#) [\[PubMed\]](#)
115. Silecchia V, Cattarozzi A, Piermarocchi S, Tavolato M. Retinal hemorrhages in a newborn with prenatal cocaine exposure. *J Clin Neonatol* 2024;13:67-9. [\[CrossRef\]](#)
116. Macones GA, Sehdev HM, Parrry S, Morgan MA, Berlin JA. The association between maternal cocaine use and placenta previa. *Am J Obstet Gynecol* 1997;177(5):1097-100. [\[CrossRef\]](#) [\[PubMed\]](#)
117. Esmer MC, Rodriguez-Soto G, Carrasco-Daza D, Iracheta ML, Del Castillo V. Cloverleaf skull and multiple congenital anomalies in a girl exposed to cocaine in utero: case report and review of the literature. *Childs Nerv Syst* 2000;16(3):176-9. [\[CrossRef\]](#) [\[PubMed\]](#)
118. Marles SL, Reed M, Evans JA. Humeroradial synostosis, ulnar aplasia and oligodactyly, with contralateral amelia, in a child with prenatal cocaine exposure. *Am J Med Genet A* 2003;116A(1):85-9. [\[CrossRef\]](#) [\[PubMed\]](#)
119. Kashiwagi M, Chaoui R, Stallmach T, Hürlimann S, Lauper U, Hebisch G. Fetal bilateral renal agenesis, phocomelia, and single umbilical artery associated with cocaine abuse in early pregnancy. *Birth Defects Res A Clin Mol Teratol* 2003;67(11):951-2. [\[CrossRef\]](#) [\[PubMed\]](#)
120. Afzal MN. Fatal double aortic arch anomaly and maternal cocaine abuse. *J Coll Physicians Surg Pak* 2003;13:166-7.
121. Finnegan J, O'Sullivan D, Boyle MA. Hypospadias and cocaine use in pregnancy. *Ir Med J* 114;6:P389.
122. Tan-Laxa MA, Sison-Switala C, Rintelman W, Ostrea EM Jr. Abnormal auditory brainstem response among infants with prenatal cocaine exposure. *Pediatrics* 2004;113(2):357-60. [\[CrossRef\]](#) [\[PubMed\]](#)
123. Katikaneni PK, Akkus NI, Tandon N, Modi K. Cocaine-induced postpartum coronary artery dissection: a case report and 80-year review of literature. *J Invasive Cardiol* 2013;25(8):E163-6. [\[PubMed\]](#)
124. Bauer CR, Langer JC, Shankaran S, Bada HS, Lester B, Wright LL, et al. Acute neonatal effects of cocaine exposure during pregnancy. *Arch Pediatr Adolesc Med* 2005;159(9):824-34. [\[CrossRef\]](#) [\[PubMed\]](#)
125. Thomas KR, Thomas SP, Hewan-Lowe KO, Pestaner JP. Fibromuscular dysplasia in association with intrauterine cocaine exposure. *Cardiovasc Pathol* 2007;16(5):313-6. [\[CrossRef\]](#) [\[PubMed\]](#)
126. Palmer JM, Indermaur MD, Tebes CC, Spellacy WN. Placenta increta and cocaine abuse in a grand multipara leading to a second trimester rupture of an unscarred uterus: a case report. *South Med J* 2008;101(8):834-5. [\[CrossRef\]](#) [\[PubMed\]](#)
127. Reynolds BC, Penman DM, Howatson AG, Jackson LA, Skeoch CH. Multifocal multi-organ ischaemia and infarction in a preterm baby due to maternal intravenous cocaine use: a case report. *J Med Case Reports* 2009;3:9324. [\[CrossRef\]](#) [\[PubMed\]](#) povucen <https://link.springer.com/content/pdf/10.1186/1752-1947-0003-0000009259.pdf>
128. Gad A, Morelli P, Decristofaro J. Perinatal isolated atrial flutter associated with maternal cocaine and opiate use in a late preterm infant. *J Matern Fetal Neonatal Med* 2010;23(9):1062-5. [\[CrossRef\]](#) [\[PubMed\]](#)

- 129.Salihi HM, Salemi JL, Aggarwal A, Steele BF, Pepper RC, Mogos MF, et al. Opioid drug use and acute cardiac events among pregnant women in the United States. *Am J Med* 2018;131(1):64-71. [\[CrossRef\]](#) [\[PubMed\]](#)
- 130.Puvabanditsin S, Garrow E, Augustin G, Titapiwatanakul R, Kuniyoshi KM. Poland-Mobius syndrome and cocaine abuse: a relook at vascular etiology. *Pediatr Neurol* 2005;32(4):285-7. [\[CrossRef\]](#) [\[PubMed\]](#)
- 131.Wennberg RP, Yin J, Miller M, Maynard A. Fetal cocaine exposure and neonatal bilirubinemia. *J Pediatr* 1994;125(4):613-6. [\[CrossRef\]](#) [\[PubMed\]](#)
- 132.van den Bor M, Walther FJ, Ebrahimi M. Decreased cardiac output in infants of mothers who abused cocaine. *Pediatrics* 1990;85(1):30-2. [\[CrossRef\]](#) [\[PubMed\]](#)
- 133.Horn PT. Persistent hypertension after prenatal cocaine exposure. *J Pediatr* 1992;121(2):288-91. [\[CrossRef\]](#) [\[PubMed\]](#)
- 134.Needlman R, Zuckerman B, Anderson GM, Mirochnick M, Cohen DJ. Cerebrospinal fluid monoamine precursors and metabolites in human neonates following in utero cocaine exposure: a preliminary study. *Pediatrics* 1993;92(1):55-60. [\[PubMed\]](#)
- 135.Gkioka E, Korou LM, Daskalopoulou A, Mitsizi A, Batsidis E, Bakoyiannis I, et al. Prenatal cocaine exposure and its impact on cognitive functions of offspring: a pathophysiological insight. *Rev Neurosci* 2016;27(5):523-34. [\[CrossRef\]](#) [\[PubMed\]](#)
- 136.Bada HS, Das A, Bauer CR, Shankaran S, Lester B, LaGasse L, et al. Impact of prenatal cocaine exposure on child behavior problems through school age. *Pediatrics* 2007;119(2): e348-e35. [\[CrossRef\]](#) [\[PubMed\]](#)
- 137.Martin MM, Graham DL, McCarthy DM, Bhide PG, Stanwood GD. Cocaine-induced neurodevelopmental deficits and underlying mechanisms. *Birth Defects Res C Embryo Today* 2016;108(2):147-73. [\[CrossRef\]](#) [\[PubMed\]](#)
- 138.Doberczak TM, Shanzer S, Senie RT, Kendal SR. Neonatal neurologic and electroencephalographic effects of intrauterine cocaine exposure. *J Pediatr* 1988;113(2):354-8. [\[CrossRef\]](#) [\[PubMed\]](#)
- 139.Morrow CE, Culbertson JL, Accornero VH, Xue L, Anthony JC, Bandstra ES. Learning disabilities and intellectual functioning in school-aged children with prenatal cocaine exposure. *Dev Neuropsychol* 2006;30(3):905-31. [\[CrossRef\]](#) [\[PubMed\]](#)
- 140.Richardson GA, Goldschmidt L, Larkby C. Effects of prenatal cocaine exposure on growth: a longitudinal analysis. *Pediatrics* 2007;120(4):e1017-27. [\[CrossRef\]](#) [\[PubMed\]](#)
- 141.Singer LT, Nelson S, Short E, Min MO, Lewis B, Russ S, et al. Prenatal cocaine exposure: drug and environmental effects at 9 years. *J Pediatr* 2008;153(1):105-11. [\[CrossRef\]](#) [\[PubMed\]](#)
- 142.Good WV, Ferriero DM, Golabi M, Kobori JA. Abnormalities of the visual system in infants to cocaine. *Ophthalmology* 1992;99:341-6. [\[CrossRef\]](#) [\[PubMed\]](#)
- 143.Block SS, Scharre JE, Moore BD. Visual anomalies in children exposed to cocaine (abstract). *Optometry* 1993;70:86A. [\[CrossRef\]](#) [\[PubMed\]](#)
- 144.Singer LT, Powers G, Kim JY, Minnes S, Min MO. Cognitive and functional outcomes at age 21 after prenatal cocaine/polydrug exposure and foster/adoptive care. *Neurotoxicol Teratol* 2023;96:107151. [\[CrossRef\]](#) [\[PubMed\]](#)
- 145.Phibbs CS, Bateman DA, Schwartz RM. The neonatal costs of maternal cocaine use. *JAMA* 1991;266(11):1521-6. [\[CrossRef\]](#) [\[PubMed\]](#)
- 146.Joyce T, Racine AD, McCalla S, Wehbeh H. The impact of prenatal exposure to cocaine on newborn costs and length of stay. *Health Serv Res* 1995;30(2):341-58. [\[CrossRef\]](#) [\[PubMed\]](#)
- 147.Stanwood GD, Levitt P. Drug exposure early in life: functional repercussions of changing neuropharmacology during sensitive periods of brain development. *Curr Opin Pharmacol* 2004;4(1):65-71. [\[CrossRef\]](#) [\[PubMed\]](#)
- 148.Minnes S, Min MO, Singer LT, Edguer M, Wu M, Thi P. Cocaine use during pregnancy and health outcome after 10 years. *Drug and Alcohol Depend* 2012;126(1-2):71-9. [\[CrossRef\]](#) [\[PubMed\]](#)
- 149.Ukah UV, Potter BJ, Paradis G, Low N, Ayoub A, Auger N. Cocaine and the long-term risk of cardiovascular disease in women. *Am J Med* 2022;135(8):993-1000. [\[CrossRef\]](#) [\[PubMed\]](#)

Pregledni rad

UDC: 618.2:613.83
doi: 10.5633 / amm.2025.0320

EFEKTI KOKAINA NA TOK I ISHOD TRUDNOĆE

Novica Bojanić¹, Jelena Milenković¹, Darija Obradović², Jelena Bojanić³,
Nataša Đinđić⁴, Stefan Ilić⁵¹Univerzitet u Nišu, Medicinski fakultet, Katedra Patofiziologija, Niš, Srbija²Univerzitet u Beogradu, Institut za fiziku Beograd, Beograd, Srbija³Zdravstveni centar Surdulica, Dom zdravlja, Služba za zdravstvenu zaštitu žena i dece, Surdulica, Srbija⁴Zavod za zdravstvenu zaštitu radnika Niš, Niš, Srbija⁵Univerzitet u Nišu, Medicinski fakultet, student doktorskih studija, Niš, Srbija

Kontakt: Novica Bojanić

Bulevar dr Zorana Đinđića 81, 18000 Niš, Srbija

E-mail: bojanicnovica@gmail.com

Epidemija zavisnosti od nedozvoljenih droga predstavlja značajan problem javnog zdravlja širom sveta. Upotreba kokaina, do kojeg se lako može doći, kod žena u fertilnom periodu može imati štetne uticaje na tok i ishod trudnoće.

Upotreba kokaina u trudnoći uzrokuje: usporen intrauterini rast ploda, abrupciju placente, povećanu učestalost prevremenog porođaja, prerano pucanje plodnih ovojnica, prisustvo mekonijuma u amnionskoj tečnosti, mrtvorodenost, neonatalni nekrotizirajući enterokolitis, neonatalnu perforaciju creva, kompletno odsustvo dijafragme, neonatalne respiratorne poremećaje, neonatalnu nekrozu potkožnog masnog tkiva, sindrom iznenadne smrti novorođenčeta, fibromuskularnu displaziju intime brojnih krvnih sudova, oštećenje sluha, krvarenje u mrežnjači, intrakranijalna krvarenja fetusa ili majke, rupturu materice, rupturu jajovoda zbog vanmaternične trudnoće, placentu previju, promene u ponašanju neonatusa, neonatalne srčane aritmije, različite kongenitalne anomalije, infarkt miokarda trudnice i dug QT interval kod porodilje.

Retrospektivne studije su pokazale da intrauterino izlaganje kokainu izaziva *major* malformacije kod novorođenčadi: urođene srčane mane, anomalije genitourinarnog sistema, mozga i lobanje, odsustvo udova, ankiloglosiju, hamartoblastom hipotalamusa i Poland–Möbius sindrom.

Pojedini autori ističu da postoji veza između kokainskog sindroma specifičnog za fetus i visoke incidencije autizma i izloženosti kokainu *in utero*. Kokain je neurobihevioralni teratogen. Naime, dugotrajno praćenje dece koja su bila izložena kokainu pre rođenja ukazalo je na štetne efekte kokaina na njihov psihofizički razvoj. Upotreba kokaina u toku trudnoće može imati mnogobrojne štetne uticaje na trudnoću i njen ishod.

Acta Medica Medianae 2025; 64(3):157–167.

Ključne reči: kokain, trudnoća, neurobihevioralni teratogen, kongenitalne anomalije

"This work is licensed under a Creative Commons Attribution 4.0 International (CC BY 4.0) Licence".